etidronate has been researched along with Disease Exacerbation in 25 studies
Etidronic Acid: A diphosphonate which affects calcium metabolism. It inhibits ectopic calcification and slows down bone resorption and bone turnover.
etidronic acid : A 1,1-bis(phosphonic acid) that is (ethane-1,1-diyl)bis(phosphonic acid) having a hydroxy substituent at the 1-position. It inhibits the formation, growth, and dissolution of hydroxyapatite crystals by chemisorption to calcium phosphate surfaces.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate the effect of intermittent cyclical etidronate treatment on radiographic progression, bone collagen markers, and clinical disease activity in patients with rheumatoid arthritis (RA)." | 9.10 | Two year randomized controlled trial of etidronate in rheumatoid arthritis: changes in serum aminoterminal telopeptides correlate with radiographic progression of disease. ( Friman, C; Koivula, MK; Konttinen, YT; Laasonen, L; Mandelin, J; Risteli, J; Valleala, H, 2003) |
| "To evaluate the role of serum osteoprotegerin (OPG) as a biochemical marker for disease activity assessment and drug monitoring in patients with rheumatoid arthritis (RA) treated with cyclical etidronate." | 9.10 | Effect of cyclical intermittent etidronate therapy on circulating osteoprotegerin levels in patients with rheumatoid arthritis. ( Koivula, MK; Konttinen, YT; Laasonen, L; Mandelin, J; Risteli, J; Valleala, H, 2003) |
| "To investigate the effect of intermittent cyclical etidronate treatment on radiographic progression, bone collagen markers, and clinical disease activity in patients with rheumatoid arthritis (RA)." | 5.10 | Two year randomized controlled trial of etidronate in rheumatoid arthritis: changes in serum aminoterminal telopeptides correlate with radiographic progression of disease. ( Friman, C; Koivula, MK; Konttinen, YT; Laasonen, L; Mandelin, J; Risteli, J; Valleala, H, 2003) |
| "To evaluate the role of serum osteoprotegerin (OPG) as a biochemical marker for disease activity assessment and drug monitoring in patients with rheumatoid arthritis (RA) treated with cyclical etidronate." | 5.10 | Effect of cyclical intermittent etidronate therapy on circulating osteoprotegerin levels in patients with rheumatoid arthritis. ( Koivula, MK; Konttinen, YT; Laasonen, L; Mandelin, J; Risteli, J; Valleala, H, 2003) |
| "To study secondary osteoporosis postmenopause in women with hemiplegia and to show the therapeutic effects of etidronate and how osteoporotic conditions relate to the activities of daily living (ADL)." | 5.09 | Prevention of secondary osteoporosis postmenopause in hemiplegia. ( Eun, SS; Hasegawa, C; Ikai, T; Kimura, C; Miyano, S; Uematsu, M, 2001) |
| " In both dose levels, cabazitaxel (4 cycles of cabazitaxel 25 mg/m + 2 cycles of cabazitaxel 20 mg/m in level 1, and 6 cycles of cabazitaxel 25 mg/m in level 2) were combined with 2 cycles of Re-HEDP 40 MBq/kg (1." | 2.84 | A Phase 1 Trial of Cabazitaxel Combined With 188Re-Hydroxyethylidene Diphosphonate in Patients With Metastatic Castration-Resistant Prostate Cancer Who Progressed on or After a Docetaxel-Containing Treatment: The ReCab Trial. ( Bloemendal, HJ; Bouman-Wammes, EW; de Klerk, JMH; van den Eertwegh, AJM; van Dodewaard-de Jong, JM; Verheul, HMW, 2017) |
| "Five years of etidronate therapy for postmenopausal osteoporosis results in significant increases in vertebral bone mineral content, and the previously observed reduction in vertebral fracture rate in the etidronate group is maintained during at least 5 years of therapy." | 2.68 | Five years of clinical experience with intermittent cyclical etidronate for postmenopausal osteoporosis. ( Genant, HK; Kollerup, G; Storm, T; Sørensen, OH; Thamsborg, G, 1996) |
| " Intravenous pamidronate is efficacious and has long been available, but its use is hindered by an impractical recommended dosing regimen of 30 mg IV over 4 h for three consecutive days." | 2.44 | A review of Paget's disease of bone with a focus on the efficacy and safety of zoledronic acid 5 mg. ( Abelson, A, 2008) |
| "A true recurrence at exactly the same site is quite unusual in algodystrophy." | 2.40 | Different patterns of extension and recurrence in algodystrophy. ( Audran, M; Bregeon, C; Legrand, E; Masson, C; Pascaretti, C; Renier, JC, 1998) |
| "Osteoporosis is widely prevalent in India and osteoporotic fractures are a common cause of morbidity and mortality." | 1.35 | Osteoporotic fracture management in India: a survey of orthopaedic surgeons. ( Lakhotia, SM, 2008) |
| " The purpose was to determine the effects of the anti-resorptive agents alone and in combination with intermittent PTH on bone formation in the mandible and a long bone in the aged ovariectomized (Ovx) rat." | 1.31 | Mandibular bone formation rates in aged ovariectomized rats treated with anti-resorptive agents alone and in combination with intermittent parathyroid hormone. ( Hunziker, J; Miller, SC; Wronski, TJ, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (8.00) | 18.2507 |
| 2000's | 17 (68.00) | 29.6817 |
| 2010's | 5 (20.00) | 24.3611 |
| 2020's | 1 (4.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sun, J | 1 |
| Gil, M | 1 |
| Khorashadi, S | 1 |
| Chen, G | 1 |
| Lee, C | 1 |
| Ishida, Y | 1 |
| Nagai, M | 1 |
| Wada, S | 1 |
| Ishikawa-Nagai, S | 1 |
| Da Silva, JD | 1 |
| van Dodewaard-de Jong, JM | 1 |
| Bouman-Wammes, EW | 1 |
| Bloemendal, HJ | 1 |
| Verheul, HMW | 1 |
| de Klerk, JMH | 1 |
| van den Eertwegh, AJM | 1 |
| Seleznev, AN | 1 |
| Sabilo, ES | 1 |
| Savin, AA | 1 |
| Riabov, AG | 1 |
| Kozlov, SA | 1 |
| Zima, LN | 1 |
| Zmievskoĭ, GN | 1 |
| Lakhotia, SM | 1 |
| Sato, Y | 1 |
| Iwamoto, J | 1 |
| Honda, Y | 1 |
| Bartlett, SJ | 1 |
| Ling, SM | 1 |
| Mayo, NE | 1 |
| Scott, SC | 1 |
| Bingham, CO | 4 |
| Torregrosa, JV | 1 |
| Durán, CE | 1 |
| Barros, X | 1 |
| Blasco, M | 1 |
| Arias, M | 1 |
| Cases, A | 1 |
| Campistol, JM | 1 |
| Meulenbeld, HJ | 1 |
| van Werkhoven, ED | 1 |
| Coenen, JL | 1 |
| Creemers, GJ | 1 |
| Loosveld, OJ | 1 |
| de Jong, PC | 1 |
| Ten Tije, AJ | 1 |
| Fosså, SD | 1 |
| Polee, M | 1 |
| Gerritsen, W | 1 |
| Dalesio, O | 1 |
| de Wit, R | 1 |
| Valleala, H | 2 |
| Laasonen, L | 2 |
| Koivula, MK | 2 |
| Mandelin, J | 2 |
| Friman, C | 1 |
| Risteli, J | 2 |
| Konttinen, YT | 2 |
| Palmedo, H | 1 |
| Manka-Waluch, A | 1 |
| Albers, P | 1 |
| Schmidt-Wolf, IG | 1 |
| Reinhardt, M | 1 |
| Ezziddin, S | 1 |
| Joe, A | 1 |
| Roedel, R | 1 |
| Fimmers, R | 1 |
| Knapp, FF | 1 |
| Guhlke, S | 1 |
| Biersack, HJ | 1 |
| Rendina, D | 1 |
| De Filippo, G | 1 |
| Mossetti, G | 1 |
| Hashiba, H | 1 |
| Aizawa, S | 1 |
| Tamura, K | 1 |
| Kogo, H | 1 |
| Buckland-Wright, JC | 2 |
| Messent, EA | 1 |
| Ward, RJ | 1 |
| Tonkin, C | 1 |
| Garnero, P | 2 |
| Cohen, SB | 2 |
| Dougados, M | 1 |
| Adami, S | 1 |
| Clauw, DJ | 1 |
| Spector, TD | 1 |
| Pelletier, JP | 2 |
| Raynauld, JP | 2 |
| Strand, V | 1 |
| Simon, LS | 1 |
| Meyer, JM | 3 |
| Cline, GA | 3 |
| Beary, JF | 3 |
| Martel-Pelletier, J | 1 |
| Berthiaume, MJ | 1 |
| Abram, F | 1 |
| Choquette, D | 1 |
| Haraoui, B | 1 |
| Mori, H | 1 |
| Okada, Y | 1 |
| Tanaka, Y | 1 |
| Brookler, KH | 1 |
| Hamid, MA | 1 |
| Aronstein, WS | 1 |
| Conaghan, PG | 1 |
| Christiansen, C | 1 |
| Abelson, A | 1 |
| Storm, T | 1 |
| Kollerup, G | 1 |
| Thamsborg, G | 1 |
| Genant, HK | 1 |
| Sørensen, OH | 1 |
| Masson, C | 1 |
| Audran, M | 1 |
| Pascaretti, C | 1 |
| Legrand, E | 1 |
| Bregeon, C | 1 |
| Renier, JC | 1 |
| Hunziker, J | 1 |
| Wronski, TJ | 1 |
| Miller, SC | 1 |
| Ikai, T | 1 |
| Uematsu, M | 1 |
| Eun, SS | 1 |
| Kimura, C | 1 |
| Hasegawa, C | 1 |
| Miyano, S | 1 |
| O'Sullivan, JM | 1 |
| McCready, VR | 1 |
| Flux, G | 1 |
| Norman, AR | 1 |
| Buffa, FM | 1 |
| Chittenden, S | 1 |
| Guy, M | 1 |
| Pomeroy, K | 1 |
| Cook, G | 1 |
| Gadd, J | 1 |
| Treleaven, J | 1 |
| Al-Deen, A | 1 |
| Horwich, A | 1 |
| Huddart, RA | 1 |
| Dearnaley, DP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Repeated Rhenium-188-HEDP Versus Radium-223-chloride in Patients With Metastatic Castration-resistant Prostate Cancer: The RaRe Study[NCT03458559] | Phase 3 | 402 participants (Anticipated) | Interventional | 2018-05-16 | Active, not recruiting | ||
| A Randomized Placebo Controlled Trial Testing The Effect of Zoledronic Acid on Hip Osteoarthritis[NCT04303026] | Phase 3 | 70 participants (Anticipated) | Interventional | 2020-03-02 | Recruiting | ||
| Altering Bone Microarchitecture and Mechanics by Off-label Pharmaceutical Intervention[NCT05204836] | Phase 1 | 56 participants (Anticipated) | Interventional | 2023-05-16 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for etidronate and Disease Exacerbation
| Article | Year |
|---|---|
A review of Paget's disease of bone with a focus on the efficacy and safety of zoledronic acid 5 mg.
Topics: Aged; Bone Density Conservation Agents; Diphosphonates; Disease Progression; Etidronic Acid; Humans; | 2008 |
Different patterns of extension and recurrence in algodystrophy.
Topics: Adult; Bone and Bones; Diagnosis, Differential; Disease Progression; Etidronic Acid; Factitious Diso | 1998 |
16 trials available for etidronate and Disease Exacerbation
| Article | Year |
|---|---|
A Phase 1 Trial of Cabazitaxel Combined With 188Re-Hydroxyethylidene Diphosphonate in Patients With Metastatic Castration-Resistant Prostate Cancer Who Progressed on or After a Docetaxel-Containing Treatment: The ReCab Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Etidronic Acid; Huma | 2017 |
[Mechanisms of formation of chronic low back pain relapse and their correction in patients with dorsopathy].
Topics: Algorithms; Anxiety; Bone Density Conservation Agents; Chronic Disease; Depression; Disease Progress | 2008 |
RETRACTED: Beneficial effect of etidronate therapy in chronically hospitalized, disabled patients with stroke.
Topics: Aged; Body Mass Index; Bone Density; Bone Density Conservation Agents; Calcium; Chronic Disease; Dis | 2010 |
Identifying common trajectories of joint space narrowing over two years in knee osteoarthritis.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Disability Evaluation; Disease Pro | 2011 |
Successful treatment of calcific uraemic arteriolopathy with bisphosphonates.
Topics: Aged; Alendronate; Alkaline Phosphatase; Arterioles; Calciphylaxis; Calcium; Comorbidity; Diphosphon | 2012 |
Randomised phase II/III study of docetaxel with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro).
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Phytogenic; Antineoplastic Com | 2012 |
Two year randomized controlled trial of etidronate in rheumatoid arthritis: changes in serum aminoterminal telopeptides correlate with radiographic progression of disease.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Biomarkers; Collagen; Collagen Type I; Dis | 2003 |
Effect of cyclical intermittent etidronate therapy on circulating osteoprotegerin levels in patients with rheumatoid arthritis.
Topics: Adult; Aged; Arthritis, Rheumatoid; Arthrography; Collagen Type I; Disease Progression; Dose-Respons | 2003 |
Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: tandomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate.
Topics: Aged; Bone Neoplasms; Disease Progression; Dose-Response Relationship, Radiation; Etidronic Acid; Hu | 2003 |
Inhibition of the progression of aortic calcification by etidronate treatment in hemodialysis patients: long-term effects.
Topics: Aortic Diseases; Bone Density; Bone Density Conservation Agents; Calcinosis; Disease Progression; Et | 2006 |
A 2 yr longitudinal radiographic study examining the effect of a bisphosphonate (risedronate) upon subchondral bone loss in osteoarthritic knee patients.
Topics: Adult; Aged; Bone Density Conservation Agents; Disease Progression; Dose-Response Relationship, Drug | 2007 |
Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis st
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Bone Density Conservation Agents; Cartilage; Disease Pro | 2006 |
Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis st
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Bone Density Conservation Agents; Cartilage; Disease Pro | 2006 |
Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis st
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Bone Density Conservation Agents; Cartilage; Disease Pro | 2006 |
Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis st
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Bone Density Conservation Agents; Cartilage; Disease Pro | 2006 |
Relationships between biochemical markers of bone and cartilage degradation with radiological progression in patients with knee osteoarthritis receiving risedronate: the Knee Osteoarthritis Structural Arthritis randomized clinical trial.
Topics: Aged; Biomarkers; Bone Density Conservation Agents; Bone Resorption; Cartilage, Articular; Collagen | 2008 |
Five years of clinical experience with intermittent cyclical etidronate for postmenopausal osteoporosis.
Topics: Aged; Bone Density; Disease Progression; Double-Blind Method; Drug Administration Schedule; Etidroni | 1996 |
Prevention of secondary osteoporosis postmenopause in hemiplegia.
Topics: Absorptiometry, Photon; Activities of Daily Living; Aged; Alkaline Phosphatase; Amino Acids; Bone De | 2001 |
High activity Rhenium-186 HEDP with autologous peripheral blood stem cell rescue: a phase I study in progressive hormone refractory prostate cancer metastatic to bone.
Topics: Bone and Bones; Bone Neoplasms; Combined Modality Therapy; Disease Progression; Etidronic Acid; Filg | 2002 |
7 other studies available for etidronate and Disease Exacerbation
| Article | Year |
|---|---|
Efficacy of bisphosphonates in detection of early enamel caries using NIR fluorescence imaging and inhibition of caries progression.
Topics: Bone Density Conservation Agents; Contrast Media; Dental Caries; Dental Enamel; Diphosphonates; Dise | 2021 |
Osteoporotic fracture management in India: a survey of orthopaedic surgeons.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Disease Progression; Etidronic Acid; | 2008 |
Paget's disease and bisphosphonates.
Topics: Administration, Oral; Alkaline Phosphatase; Diphosphonates; Disease Progression; Etidronic Acid; Hum | 2005 |
Correlation between bone lesion changes and cartilage volume loss in patients with osteoarthritis of the knee as assessed by quantitative magnetic resonance imaging over a 24-month period.
Topics: Analysis of Variance; Bone and Bones; Bone Cysts; Cartilage, Articular; Diphosphonates; Disease Prog | 2008 |
Etidronate for the treatment of progressive tumoral calcinosis in hemodialysis patients.
Topics: Adult; Bone Density Conservation Agents; Calcinosis; Disease Progression; Etidronic Acid; Humans; Ki | 2007 |
Clinical management of a patient with a 12-year history of a balance disorder.
Topics: Aged; Bone Density Conservation Agents; Calcium; Disease Progression; Drug Therapy, Combination; Eti | 2007 |
Mandibular bone formation rates in aged ovariectomized rats treated with anti-resorptive agents alone and in combination with intermittent parathyroid hormone.
Topics: Analysis of Variance; Animals; Bone Resorption; Calcitonin; Calcium Channel Blockers; Diphosphonates | 2000 |